By Max Braht, Director of Business Development, LSN
Across Europe, early-stage life science innovation is not constrained by a lack of capital—it is constrained by a lack of translation. Breakthrough science continues to emerge from universities, hospitals, and startups across the continent, yet too few assets successfully transition from discovery into opportunities the global market can underwrite.
To address this gap, Life Science Nation is launching a new three-part seminar series tailored specifically for the European life science ecosystem. The program focuses on the critical space between discovery and investment decision-making—where promising science often stalls before capital ever has the chance to engage.
Designed for founders, investors, accelerators, universities, public agencies, and ecosystem leaders, the series centers on companies at the seed, Series A, and Series B stages—where signal is still forming and legibility matters more than exposure.
What the series will explore
Session I — Tuesday, February 17 | 10:00 AM ET / 4:00 PM CET – Sign Up
Why Good Science Fails Before Capital Ever Says No
How early-stage assets stall long before diligence begins, and why this is a structural translation issue rather than a capital shortage from an investor’s perspective.
Session II — Tuesday, February 24 | 10:00 AM ET / 4:00 PM CET – Sign Up
Legibility, Signal, and the Real Work Between Seed and Series B
What European and global investors actually require to underwrite early-stage risk, and how signal is formed across scientific, regulatory, and commercial dimensions.
Session III — Wednesday, March 4 | 10:00 AM ET / 4:00 PM CET – Sign Up
Partnering Is Not Exposure. It Is Filtration
How different partnering environments serve different stages of development, and how European companies can avoid wasting time and momentum by engaging the wrong forum too early.
This is not a fundraising seminar and not a pitch workshop. It is a practical framework for understanding how early-stage European innovation becomes readable—to capital, to strategic partners, and to the global market.
| Register for RESI Europe |
Next Phase Newsletter 
Leave a comment